AI
Monday, December 29, 2025 9:51:32 PM
”30 year old, obsolete technology”
PD-1 checkpoint inhibitors have been commercially available only since 2014, & PD-1 research with other immunotherapy modalities has only recently begun…
Targeted COMBO therapy regimens represent NEW innovations, & Roswell’s aDC1 technology is relatively new as a combo agent in clinical trials.
Dr. Kalinski
Fact ✅️: NWBO’s IP portfolio includes more than one pipeline product in active clinical development. For example, the aDC1 platform that NWBO licensed from Roswell Park in New York has reached PII in combo with Merck’s pembrolizumab. NEXT GEN COMBOS will make some significant waves going forward!
Merck is only one example, but the industry overall is trending toward combo research to enhance efficacy & reduce toxicity for patients.
Next Generation Dendritic Cell Treatments
AACR IMMUNO-ONCOLOGY CONFERENCE 2026
Pitt BioForge
Roswell Park Dendritic Cell Technology & IP
DCVax-L Combo PII UCLA
AI Fact-Checking
Believe carefully. This is the greatest and most powerful lesson that I have learned since arriving on Earth. Examine what you believe about yourself most importantly, and then believe carefully as you interact with the world.
Recent NWBO News
Cannabix Technologies Announces First Delivery of Marijuana Breath Test (MBT) to a Major Construction Client • BLOZF • Mar 19, 2026 12:45 PM
ECGI Building in Crypto's Top-Performing Sector as Tokenized Real-World Assets Surge Past $26 Billion • ECGI • Mar 19, 2026 8:30 AM
Advances in Domestic Heavy Rare Earth Minerals Production Essential for North American Defense Stockpiles • ALOY • Mar 18, 2026 9:00 AM
ECGI Advances $10M Mortgage Tokenization Pilot as SEC Interpretation Adds Clarity • ECGI • Mar 18, 2026 8:45 AM
ECGI Advances Mortgage Tokenization Pilot as Institutional Market Rails Continue to Develop • ECGI • Mar 17, 2026 8:30 AM
Record Gold Prices Reshape Economics of New Mine Development • SNWGF • Mar 16, 2026 10:46 AM
